Search

Regina M. Deberry

Examiner (ID: 18586)

Most Active Art Unit
1647
Art Unit(s)
1647
Total Applications
1049
Issued Applications
415
Pending Applications
152
Abandoned Applications
510

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 19432578 [patent_doc_number] => 20240301076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ANTI-CXCR2 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/666190 [patent_app_country] => US [patent_app_date] => 2024-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18666190 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/666190
ANTI-CXCR2 ANTIBODIES AND USES THEREOF May 15, 2024 Pending
Array ( [id] => 19998417 [patent_doc_number] => 20250136639 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => Method for purifying PEGylated erythropoietin [patent_app_type] => utility [patent_app_number] => 18/645245 [patent_app_country] => US [patent_app_date] => 2024-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18645245 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/645245
Method for purifying PEGylated erythropoietin Apr 23, 2024 Pending
Array ( [id] => 19830986 [patent_doc_number] => 20250082772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-13 [patent_title] => ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 18/637050 [patent_app_country] => US [patent_app_date] => 2024-04-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17776 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18637050 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/637050
ANTIBODY-DRUG CONJUGATE Apr 15, 2024 Pending
Array ( [id] => 19345224 [patent_doc_number] => 20240254187 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION [patent_app_type] => utility [patent_app_number] => 18/624726 [patent_app_country] => US [patent_app_date] => 2024-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12288 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18624726 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/624726
DUAL-FUNCTION PROTEIN FOR LIPID AND BLOOD GLUCOSE REGULATION Apr 1, 2024 Abandoned
Array ( [id] => 19233782 [patent_doc_number] => 20240190974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => ANTI-ACVR1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/584551 [patent_app_country] => US [patent_app_date] => 2024-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18584551 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/584551
ANTI-ACVR1 ANTIBODIES AND USES THEREOF Feb 21, 2024 Pending
Array ( [id] => 19447361 [patent_doc_number] => 20240307491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION [patent_app_type] => utility [patent_app_number] => 18/444110 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444110 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/444110
ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION Feb 15, 2024 Abandoned
Array ( [id] => 19418502 [patent_doc_number] => 20240294625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-05 [patent_title] => Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody [patent_app_type] => utility [patent_app_number] => 18/401874 [patent_app_country] => US [patent_app_date] => 2024-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18401874 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/401874
Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody Jan 1, 2024 Abandoned
Array ( [id] => 19613318 [patent_doc_number] => 20240398998 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/396187 [patent_app_country] => US [patent_app_date] => 2023-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18396187 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/396187
ACTIVATABLE ANTIBODIES THAT BIND EPIDERMAL GROWTH FACTOR RECEPTOR AND METHODS OF USE THEREOF Dec 25, 2023 Issued
Array ( [id] => 19127229 [patent_doc_number] => 20240132582 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/538465 [patent_app_country] => US [patent_app_date] => 2023-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18538465 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/538465
ANTI-IL-36 ANTIBODIES AND METHODS OF USE THEREOF Dec 12, 2023 Abandoned
Array ( [id] => 19473891 [patent_doc_number] => 12103967 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Bispecific anti-CCL2 antibodies [patent_app_type] => utility [patent_app_number] => 18/509252 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 36 [patent_no_of_words] => 90169 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 283 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509252 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/509252
Bispecific anti-CCL2 antibodies Nov 13, 2023 Issued
Array ( [id] => 19265384 [patent_doc_number] => 20240209083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => ANTIBODIES AGAINST TIM3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/481884 [patent_app_country] => US [patent_app_date] => 2023-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18481884 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/481884
ANTIBODIES AGAINST TIM3 AND USES THEREOF Oct 4, 2023 Abandoned
Array ( [id] => 18922985 [patent_doc_number] => 20240025989 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => TREATMENT OF HIDRADENITIS SUPPURATIVA [patent_app_type] => utility [patent_app_number] => 18/478374 [patent_app_country] => US [patent_app_date] => 2023-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6863 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478374 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/478374
TREATMENT OF HIDRADENITIS SUPPURATIVA Sep 28, 2023 Abandoned
Array ( [id] => 18921428 [patent_doc_number] => 20240024432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 18/464025 [patent_app_country] => US [patent_app_date] => 2023-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50777 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18464025 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/464025
ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES Sep 7, 2023 Abandoned
Array ( [id] => 19201484 [patent_doc_number] => 20240173383 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => COMPOSITIONS COMPRISING RELAXIN AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/215317 [patent_app_country] => US [patent_app_date] => 2023-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28239 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18215317 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/215317
COMPOSITIONS COMPRISING RELAXIN AND METHODS OF USE THEREOF Jun 27, 2023 Pending
Array ( [id] => 19034178 [patent_doc_number] => 20240083993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => BISPECIFIC ANTI-CCL2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/335941 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 103578 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335941 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/335941
BISPECIFIC ANTI-CCL2 ANTIBODIES Jun 14, 2023 Pending
Array ( [id] => 18923016 [patent_doc_number] => 20240026020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ANTI-OPG ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/312897 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312897 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/312897
Anti-OPG antibodies May 4, 2023 Issued
Array ( [id] => 18923016 [patent_doc_number] => 20240026020 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => ANTI-OPG ANTIBODIES [patent_app_type] => utility [patent_app_number] => 18/312897 [patent_app_country] => US [patent_app_date] => 2023-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18312897 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/312897
Anti-OPG antibodies May 4, 2023 Issued
Array ( [id] => 18649501 [patent_doc_number] => 20230295317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2 [patent_app_type] => utility [patent_app_number] => 18/298466 [patent_app_country] => US [patent_app_date] => 2023-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18298466 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/298466
ANTIBODIES AGAINST HUMAN AND CANINE IL-13RA2 Apr 10, 2023 Pending
Array ( [id] => 18739644 [patent_doc_number] => 20230348606 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS [patent_app_type] => utility [patent_app_number] => 18/126528 [patent_app_country] => US [patent_app_date] => 2023-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18126528 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/126528
METHODS FOR TREATING SEVERE ASTHMA IN PATIENTS WITH NASAL POLYPOSIS Mar 26, 2023 Abandoned
Array ( [id] => 18647859 [patent_doc_number] => 20230293635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-21 [patent_title] => METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE [patent_app_type] => utility [patent_app_number] => 18/156016 [patent_app_country] => US [patent_app_date] => 2023-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18156016 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/156016
METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE Jan 17, 2023 Abandoned
Menu